Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot near-infrared fluorescence molecular endoscopy study of labeled vedolizumab in inflammatory bowel disease
NL-OMON54932Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of vedolizumab in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (3 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Fluorescent signal quantification, Correlation of fluorescence with clinical response and remission and 3 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON54932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54932.